Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM46F5X)

• Drug Name: isobutylmethylxanthine Drug Info
• Synonyms: 3-Isobutyl-1-methylxanthine; IBMX; 28822-58-4; 1-METHYL-3-ISOBUTYLXANTHINE; Methylisobutylxanthine; 3-Isobutyl-1-methyl-1H-purine-2,6(3H,7H)-dione; Xanthine, 3-isobutyl-1-methyl-; 3-Isobutyl-1-methyxanthine; 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-(2-methylpropyl)-; Methyl-isobutylxanthine; 3-isobutyl-1-methylxanthine (ibmx); UNII-TBT296U68M; 3-Isobutyl 1-methylxanthine; NSC 165960; CCRIS 4290; CHEBI:34795; 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione; 3-isobutyl-1-methyl-7H-xanthine; methylisobutylxanthine; 3-Isobutyl-1-methyl-3,9-dihydro-purine-2,6-dione; 3-ISOBUTYL-1-METHYLXANTHINE

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1] , [2] , [3]

• Cross-matching ID:
  PubChem CID: 3758
  ChEBI ID: CHEBI:34795
  CAS Number: CAS 28822-58-4
  TTD Drug ID: DM46F5X

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 4D (PDE4D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Papaverine	DMCA9QP	Spasm	MB47.3	Approved	[2]
DENBUFYLLINE	DM2R15Q	Cognitive impairment	6D71	Phase 3	[7]
SOTB07	DMIG4OX	Asthma	CA23	Phase 3	[8]
AN-2898	DMDK7CL	Atopic dermatitis	EA80	Phase 2	[9]
GPD-1116	DMOQ7YI	Asthma	CA23	Phase 2	[10]
TA-7906	DMZTAJL	Atopic dermatitis	EA80	Phase 2	[11]
HT-0712	DM2WP8F	Cognitive impairment	6D71	Phase 2	[8]
TOFIMILAST	DMLCUAS	Chronic obstructive pulmonary disease	CA22	Phase 2	[12]
AWD-12-281	DMVADGZ	Rhinitis	FA20	Phase 2	[13]
LIRIMILAST	DMD4KAU	Chronic obstructive pulmonary disease	CA22	Phase 2	[12]

Drug(s) Targeting Phosphodiesterase 5A (PDE5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tadalafil	DMJZHT1	Erectile dysfunction	HA01.1	Approved	[14]
Udenafil	DM1IQRP	Erectile dysfunction	HA01.1	Approved	[15]
Vardenafil	DMTBGW8	Erectile dysfunction	HA01.1	Approved	[16]
Dipyridamole	DMXY30O	Hypertension	BA00-BA04	Approved	[17]
Papaverine	DMCA9QP	Spasm	MB47.3	Approved	[18]
Avanafil	DM75CXN	Erectile dysfunction	HA01.1	Approved	[12]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[19]
ICARIIN	DMOJQGT	N. A.	N. A.	Phase 3	[20]
EXISULIND	DMBY56U	Colorectal cancer	2B91.Z	Phase 3	[21]
PF-489791	DM3C8GQ	Chronic obstructive pulmonary disease	CA22	Phase 2	[22]

Drug(s) Targeting Phosphodiesterase 4B (PDE4B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DENBUFYLLINE	DM2R15Q	Cognitive impairment	6D71	Phase 3	[7]
SOTB07	DMIG4OX	Asthma	CA23	Phase 3	[23]
AN-2898	DMDK7CL	Atopic dermatitis	EA80	Phase 2	[9]
GPD-1116	DMOQ7YI	Asthma	CA23	Phase 2	[10]
TA-7906	DMZTAJL	Atopic dermatitis	EA80	Phase 2	[11]
HT-0712	DM2WP8F	Cognitive impairment	6D71	Phase 2	[23]
TOFIMILAST	DMLCUAS	Chronic obstructive pulmonary disease	CA22	Phase 2	[24]
AWD-12-281	DMVADGZ	Rhinitis	FA20	Phase 2	[13]
LIRIMILAST	DMD4KAU	Chronic obstructive pulmonary disease	CA22	Phase 2	[24]
Oglemilast	DMVC90W	Asthma	CA23	Phase 2	[25]

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[26]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[27]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[28]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[29]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[30]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[31]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[32]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[29]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[29]
Methylthioadenosine	DMC8J6F	Multiple sclerosis	8A40	Terminated	[33]

Drug(s) Targeting Phosphodiesterase 1 (PDE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vinpocetine	DMVN2E6	Ischemic stroke	8B11.5Z	Approved	[34]
ITI-214	DM08TH3	Parkinson disease	8A00.0	Phase 1/2	[35]
Zaprinast	DMGH3T5	N. A.	N. A.	Terminated	[36]
BIBW-22	DMXIH3Q	Solid tumour/cancer	2A00-2F9Z	Terminated	[37]
S,S-(2-Hydroxyethyl)Thiocysteine	DMLPAD8	Discovery agent	N.A.	Investigative	[38]
BUFROLIN	DM61F5W	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Phosphodiesterase 4A (PDE4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dyphylline	DM8DZC1	Acute bronchial asthma	CA23	Approved	[39]
Enprofylline	DMFYZKN	Asthma	CA23	Approved	[40]
DENBUFYLLINE	DM2R15Q	Cognitive impairment	6D71	Phase 3	[7]
SOTB07	DMIG4OX	Asthma	CA23	Phase 3	[41]
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[42]
AN-2898	DMDK7CL	Atopic dermatitis	EA80	Phase 2	[9]
GPD-1116	DMOQ7YI	Asthma	CA23	Phase 2	[10]
TA-7906	DMZTAJL	Atopic dermatitis	EA80	Phase 2	[11]
HT-0712	DM2WP8F	Cognitive impairment	6D71	Phase 2	[41]
TOFIMILAST	DMLCUAS	Chronic obstructive pulmonary disease	CA22	Phase 2	[43]

Drug(s) Targeting Adenosine A2a receptor (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Orthostatic hypotension	BA21	Approved	[44]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[45]
Regadenoson	DM76VHG	Radionuclide imaging	N.A.	Approved	[12]
Tozadenant	DMATC14	Parkinson disease	8A00.0	Phase 3	[46]
Binodenoson	DMVHF8G	Hypertension	BA00-BA04	Phase 3	[47]
Apadenoson	DMD8QTC	Coronary artery disease	BA80	Phase 3	[48]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[27]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[49]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[50]
BIIB014	DMH7RJ1	Parkinson disease	8A00.0	Phase 2	[51]

Drug(s) Targeting Phosphodiesterase 2A (PDE2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[42]
CP-461	DMEYMTX	Inflammatory bowel disease	DD72	Phase 2	[52]
ND7001	DMUBTC6	Mood disorder	6A60-6E23	Phase 1	[53]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1	DMC8935	N. A.	N. A.	Patented	[54]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2	DM4CSBD	N. A.	N. A.	Patented	[54]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2	DMS3ROL	N. A.	N. A.	Patented	[54]
Triazolo-pyridine derivative 5	DM1R205	N. A.	N. A.	Patented	[54]
PMID27321640-Compound-58	DM0NYK3	N. A.	N. A.	Patented	[54]
Triazolo-pyridine derivative 4	DM5ZQKS	N. A.	N. A.	Patented	[54]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3	DMZ61T8	N. A.	N. A.	Patented	[54]

Drug(s) Targeting Adenosine A2b receptor (ADORA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[55]
Vidarabine	DM0N85H	Herpes simplex virus infection	1F00	Approved	[55]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[27]
YT-146	DM3YVKQ	Hypertension	BA00-BA04	Phase 2	[56]
AB928	DMDOXMN	Metastatic colorectal cancer	2B91	Phase 1/2	[57]
KF-17837	DMQ6DLZ	Parkinson disease	8A00.0	Phase 1	[58]
Xanthine	DMFBOQ7	Apnea	MD11.0	Phase 1	[59]
CVT-6883	DMY84TW	Asthma	CA23	Phase 1	[60]
PBF-1129	DMOPGXM	Non-small-cell lung cancer	2C25.Y	Phase 1	[57]
PF-1913539	DMXEU14	Alzheimer disease	8A20	Discontinued in Phase 3	[61]

Drug(s) Targeting Phosphodiesterase 3A (PDE3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[6]
Aminophylline	DML2NIB	Bronchial asthma	CA23	Approved	[62]
Anagrelide	DMSQ8MD	Thrombocythemia	3B63	Approved	[63]
Enoximone	DMQVZJD	Congestive heart failure	BD10	Approved	[64]
VESNARINONE	DMBKX3C	Cardiac failure	BD10-BD13	Approved	[65]
BEMORADAN	DMUL6GY	Heart failure	BD10-BD13	Phase 2	[12]
CI-930	DMADPQX	N. A.	N. A.	Discontinued in Phase 2	[66]
EMD-53998	DMVS8IE	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 1	[12]
IMAZODAN	DMWTFO3	N. A.	N. A.	Terminated	[67]
LAS-31180	DMW2K1L	Heart failure	BD10-BD13	Terminated	[68]

Drug(s) Targeting Adenosine A1 receptor (ADORA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Orthostatic hypotension	BA21	Approved	[44]
Rolofylline	DMSZPR3	Heart failure	BD10-BD13	Phase 3	[69]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[27]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[50]
SELODENOSON	DMQM3IX	Cardiac arrhythmias	BC9Z	Phase 2	[70]
Apaxifylline	DMQMV9F	Cognitive impairment	6D71	Phase 2	[71]
SLV320	DM867BJ	Heart failure	BD10-BD13	Phase 2	[72]
DTI-0009	DMV84OK	Atrial fibrillation	BC81.3	Phase 2	[70]
Capadenoson	DMYWO62	Atrial fibrillation	BC81.3	Phase 2	[73]
BAY 1067197	DM4JGNH	Heart failure	BD10-BD13	Phase 2	[74]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A1 receptor (ADORA1)	TTK25J1	AA1R_HUMAN	Antagonist	[4] , [3]
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Inhibitor	[5]
Adenosine A2b receptor (ADORA2B)	TTNE7KG	AA2BR_HUMAN	Inhibitor	[3]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[3]
Phosphodiesterase 1 (PDE1)	TTHQENC	NOUNIPROTAC	Inhibitor	[6]
Phosphodiesterase 2A (PDE2A)	TTJGW1Z	PDE2A_HUMAN	Inhibitor	[2] , [6]
Phosphodiesterase 3A (PDE3A)	TT06AWU	PDE3A_HUMAN	Inhibitor	[6]
Phosphodiesterase 4A (PDE4A)	TTZ97H5	PDE4A_HUMAN	Inhibitor	[6]
Phosphodiesterase 4B (PDE4B)	TTVIAT9	PDE4B_HUMAN	Inhibitor	[6]
Phosphodiesterase 4D (PDE4D)	TTSKMI8	PDE4D_HUMAN	Inhibitor	[2] , [6]
Phosphodiesterase 5A (PDE5A)	TTJ0IQB	PDE5A_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 388).
• [2] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [3] Adenosine receptors: targets for future drugs. J Med Chem. 1982 Mar;25(3):197-207.
• [4] Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. J Biol Chem. 1994 Dec 23;269(51):32077-84.
• [5] Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8.
• [6] A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
• [7] Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
• [9] An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
• [10] Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
• [11] Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [13] The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
• [14] Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
• [15] Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
• [16] The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
• [17] Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
• [18] Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
• [19] cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
• [20] Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
• [21] Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
• [22] Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
• [24] Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
• [25] Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290.
• [26] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [27] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [28] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [29] 2011 Pipeline of Can-Fite BioPharm.
• [30] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [31] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [32] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [33] Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
• [34] Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401.
• [35] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [36] The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62.
• [37] BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol Pharmacol. 1996 Sep;50(3):482-92.
• [38] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [39] Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
• [40] Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62.
• [41] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
• [42] The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
• [43] GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54.
• [44] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [45] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [46] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
• [47] Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
• [48] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
• [49] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [50] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [51] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
• [52] Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83.
• [53] Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures. Neurosignals. 2013;21(3-4):197-212.
• [54] Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
• [55] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [56] Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
• [57] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [58] Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
• [59] Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
• [60] GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
• [61] Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75.
• [62] Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
• [63] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
• [64] Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
• [65] Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
• [66] Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
• [67] 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
• [68] Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
• [69] Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
• [70] Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
• [71] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
• [72] Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
• [73] A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
• [74] Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.